



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

22nd November 2022

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Street, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir

Sub: Disclosure of Related Party Transactions pursuant to SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

In compliance with Regulation 23(9) of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we enclose herewith disclosure of Related Party Transactions for the half year ended on September 30, 2022, in the required format.

This is for your information and record

Thanking you

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE HALF YEAR ENDED SEPTEMBER 30, 2022																	
(In accordance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)																	
(Amount in INR Million)																	
Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.																	
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Value of the related party transaction as approved by the audit committee* (rounded off Rs.in Millions)	Value of transaction during the reporting period (rounded off Rs.In Millions)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance as on 01/04/2022	Closing balance as on 30/09/2022	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured
1	Natco Pharma Limited		Natco Pharma (Canada) Inc. Canada		Subsidiary Company	Sale of Products	301.85	301.85	-14.91	144.66							
2	Natco Pharma Limited		Natco Pharma Asia Pte Ltd, Singapore		Subsidiary Company	Sale of Products	19.14	19.14	47.85	0							
3	Natco Pharma Limited		Natcofarma Do Brasil Ltda., Brazil		Stedp down Subsidiary Company	Sale of Products	248.50	248.50	169	259.79							
						Corporate Guarantee Given	-	-	299	299							
						Financial Gurantee Liability	-	-	8	5.67							
4	Natco Pharma Limited		Natco Pharma Australia Pty Ltd., Australia		Subsidiary Company	Investment in Equity Shares	11.01	11.01									
5	Natco Pharma Limited		Natco Pharma Inc., United States of America		Subsidiary Company	Investment in Equity Shares	521.34	521.34									
6	Natco Pharma Limited		Natco Lifesciences Philippines Inc., Philippines		Subsidiary Company	Sale of Products	5.49	5.49	3.27	7.76							
						Interest income on Loan	0.12	0.12	0.11	0.06							
						Loan given	-	-	4.59	4.89							
7	Natco Pharma Limited		Time Cap Pharma Labs Private Limited		Entities in which Directors have control or have significant influence	Rental Exepense	3.30	3.30		0							
8	Natco Pharma Limited		Natco Trust		Entities in which Directors have control or have significant influence	Donations	-	-									
						Rentsl Income	0.03	0.03									
						Contribution to CSR Activities	49.50	49.50									
9	Natco Pharma Limited		V C Nannapaneni		Key Management Personnel	Managerial Remuneration	9.75	9.75	0.85	0.78							
						Rental Exepense	1.50	1.50									
10	Natco Pharma Limited		Rajeev Nannapaneni		Key Management Personnel	Managerial Remuneration	9.00	9.00	1.26	0.77							
						Rental Exepense	1.50	1.50									
11	Natco Pharma Limited		Potluri Prasad Sivaramakrishna		Key Management Personnel	Managerial Remuneration	7.90	7.90	0.64	0.74							
						Loan given			0.39	0.39							
12	Natco Pharma Limited		Dr.Lingrao Donthineni		Key Management Personnel	Managerial Remuneration	7.90	7.90	0.65	0.74							
						Loan given			28.57	28.57							
13	Natco Pharma Limited		Dr. Pavan Bhat Ganapati		Key Management Personnel	Managerial Remuneration	26.41	26.41	0	0.61							
14	Natco Pharma Limited		S V V N Appa Rao		Chief Financial Officer	Managerial remuneration	3.82	3.82	0.18	0.38							
15	Natco Pharma Limited		Mr.Venkart Ramesh Chekuri		Company Secretary	Managerial remuneration	1.72	1.72	-	0.06							
16	Natco Pharma Limited		Govinda Prasad Dasu		Independent Director	Sitting fee	0.30	0.30									
17	Natco Pharma Limited		Leela Digumarti		Independent Director	Sitting fee	0.08	0.08									
18	Natco Pharma Limited		Umamaheshwararao Naidu Madireddi		Independent Director	Sitting fee	0.35	0.35									
19	Natco Pharma Limited		Sreerama Muerthy Gubbala		Independent Director	Sitting fee	0.40	0.40									
20	Natco Pharma Limited		Venkateswara Rao Thallapaka		Independent Director	Sitting fee	0.33	0.33									

Note: 1. *As per the provisions of the Companies Act, 2013 and/or approval of the Audit Committee or Board of Directors or shareholders as applicable
2. The PAN details are not to be included in the disclosure pursuant to guidance note issued by the stock exchanges.
3. Amounts have been rounded off to nearest million in financial statements whereas in the above statement, the company provided values in two digits.